AM679

AM679 is a potent, selective 5-lipoxygenase-activating protein (FLAP) inhibitor with an IC50 of 2 nM in a human FLAP membrane binding assay. AM679 markedly reduces the respiratory syncytial virus-driven ocular pathology as well as the synthesis of cysteinyl leukotrienes (CysLTs) in the eye[1].

Product Specifications

CAS Number

[1206880-66-1]

UNSPSC

12352005

Target

FLAP

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/AM679.html

Purity

99.72

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=C(C)N1C2=CC=CC=C2C[C@H]1COC3=CC=C(N(CC4=CC=C(C5=NC=C(OC)C=N5)C=C4)C(CC(C)(C(O)=O)C)=C6SC(C)(C)C)C6=C3

Molecular Formula

C40H44N4O5S

Molecular Weight

692.87

References & Citations

[1]Stock, N, et al. 5-Lipoxygenase-activating protein inhibitors. Part 2: 3-{5- ((S) -1-Acetyl-2,3-dihydro-1H-indol-2-ylmethoxy) -3-tert-butylsulfanyl-1-[4- (5-methoxy-pyrimidin-2-yl) -benzyl]-1H-indol-2-yl}-2,2-dimethyl-propionic acid (AM679) -A potent FLAP inhibitor. Bioorganic & Medicinal Chemistry Letters (2010), 20 (1), 213-217.|[2]Musiyenko, A, et al. A novel 5-lipoxygenase-activating protein inhibitor, AM679, reduces inflammation in the respiratory syncytial virus-infected mouse eye. Clinical and Vaccine Immunology (2009), 16 (11), 1654-1659.